Is there a role for incorporating local therapy into the management of oligometastatic EGFR-mutant NSCLC with curative intent?   

If so, what is your approach to sequencing and timing of targeted therapy and local therapy?

Answer from: Medical Oncologist at Community Practice
Medical Oncologist at Gerard J Ventura MD, FACP
What about a more common situation-  a patien...
Sign in or Register to read more